Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
Behind the FDA Approval of Dostarlimab/Chemo for dMMR/MSI-H Endometrial Cancer
August 1st 2023Matthew Powell, MD, discusses findings from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial of dostarlimab in combination with chemotherapy for patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.
Watch
Niraparib Maintenance Improves Survival in BRCA Wild-Type Ovarian Cancer
August 1st 2023In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.
Read More
Considering Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
July 28th 2023According to Bradley J. Monk, MD, FACS, FACOG, et al, multiple studies have shown the potential of tisotumab vedotin in patients with recurrent or metastatic cervical cancer. More evidence is needed before the oncology community can fully adopt its use.
Read More
The State of the Targeted Therapy Landscape for CLL
July 26th 2023In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.
Read More
Gasparetto Reviews Data for Selinexor Combination Regimen in R/R Multiple Myeloma
July 25th 2023During a Targeted Oncology Case-Based Roundtable event, Cristina Gasparetto, MD, discussed the case of a patient with stage I multiple myeloma and highlighted outcomes of the phase 3 BOSTON trial.
Read More
TKIs Continue to Improve the Treatment Paradigm for RAI-Refractory DTC
July 24th 2023In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.
Read More
Prior Pluvicto Shortage Led to Long Waiting Lists for Patients With mCRPC
July 22nd 2023Roby Thomas, MD, discusses the shortage of lutetium Lu 177 vipivotide tetraxetan, and how it had affected patients with metastatic castration-resistant prostate cancer being treated at UPMC Hillman Cancer Center.
Watch
EXCEED-ET Investigates an Alternative Option for Disease Modification in Essential Thrombocytopenia
July 16th 2023In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.
Read More